11/29
08:50 am
mlys
A Look at Mineralys Therapeutics (MLYS) Valuation After Findell Capital's Major New Investment [Yahoo! Finance]
Medium
Report
A Look at Mineralys Therapeutics (MLYS) Valuation After Findell Capital's Major New Investment [Yahoo! Finance]
11/26
05:38 pm
mlys
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
11/26
04:05 pm
mlys
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
11/12
08:07 am
mlys
Mineralys Therapeutics (NASDAQ:MLYS) had its price target raised by analysts at HC Wainwright from $52.00 to $56.00. They now have a "buy" rating on the stock.
Low
Report
Mineralys Therapeutics (NASDAQ:MLYS) had its price target raised by analysts at HC Wainwright from $52.00 to $56.00. They now have a "buy" rating on the stock.
11/11
09:44 am
mlys
Mineralys Therapeutics (NASDAQ:MLYS) had its price target raised by analysts at Wells Fargo & Company from $50.00 to $55.00. They now have an "overweight" rating on the stock.
Medium
Report
Mineralys Therapeutics (NASDAQ:MLYS) had its price target raised by analysts at Wells Fargo & Company from $50.00 to $55.00. They now have an "overweight" rating on the stock.
11/11
12:30 am
mlys
Mineralys Therapeutics Inc (MLYS) Q3 2025 Earnings Call Highlights: Strong Financial Position ... [Yahoo! Finance]
Medium
Report
Mineralys Therapeutics Inc (MLYS) Q3 2025 Earnings Call Highlights: Strong Financial Position ... [Yahoo! Finance]
11/10
04:19 pm
mlys
Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
11/10
04:05 pm
mlys
Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Medium
Report
Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
11/8
07:05 pm
mlys
Why Mineralys Therapeutics (MLYS) Is Up After Positive Lorundrostat Phase 3 Data and FDA Filing Plans [Yahoo! Finance]
High
Report
Why Mineralys Therapeutics (MLYS) Is Up After Positive Lorundrostat Phase 3 Data and FDA Filing Plans [Yahoo! Finance]
11/7
07:00 pm
mlys
Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025 [Yahoo! Finance]
High
Report
Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025 [Yahoo! Finance]
11/7
06:10 pm
mlys
Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025
High
Report
Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025
11/5
04:21 pm
mlys
Mineralys Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Medium
Report
Mineralys Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]
11/5
04:05 pm
mlys
Mineralys Therapeutics to Participate in Upcoming Investor Conferences
Medium
Report
Mineralys Therapeutics to Participate in Upcoming Investor Conferences
11/3
08:00 am
mlys
Mineralys Therapeutics to Announce Third Quarter 2025 Financial Results and Host Conference Call on Monday, November 10, 2025
Medium
Report
Mineralys Therapeutics to Announce Third Quarter 2025 Financial Results and Host Conference Call on Monday, November 10, 2025
10/30
08:08 am
mlys
Mineralys Therapeutics (NASDAQ:MLYS) had its price target raised by analysts at HC Wainwright from $42.00 to $52.00. They now have a "buy" rating on the stock.
Low
Report
Mineralys Therapeutics (NASDAQ:MLYS) had its price target raised by analysts at HC Wainwright from $42.00 to $52.00. They now have a "buy" rating on the stock.
10/25
12:09 pm
mlys
Mineralys Therapeutics (NASDAQ:MLYS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Mineralys Therapeutics (NASDAQ:MLYS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/21
08:00 am
mlys
Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 2 Explore-CKD Trial of Lorundrostat at American Society of Nephrology (ASN) Kidney Week 2025
Low
Report
Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 2 Explore-CKD Trial of Lorundrostat at American Society of Nephrology (ASN) Kidney Week 2025
9/30
08:04 pm
mlys
Mineralys Therapeutics, Inc. (MLYS) Shows Positive Phase 3 HTN Results, Blood Pressure Drops in High-Risk Groups [Yahoo! Finance]
Medium
Report
Mineralys Therapeutics, Inc. (MLYS) Shows Positive Phase 3 HTN Results, Blood Pressure Drops in High-Risk Groups [Yahoo! Finance]
9/30
08:00 am
mlys
Mineralys Therapeutics Completes Enrollment in Phase 2 EXPLORE-OSA Trial of Lorundrostat in Obstructive Sleep Apnea and Hypertension
Low
Report
Mineralys Therapeutics Completes Enrollment in Phase 2 EXPLORE-OSA Trial of Lorundrostat in Obstructive Sleep Apnea and Hypertension
9/11
08:42 am
mlys
Mineralys Therapeutics (NASDAQ:MLYS) had its price target raised by analysts at Wells Fargo & Company from $26.00 to $50.00. They now have an "overweight" rating on the stock.
Medium
Report
Mineralys Therapeutics (NASDAQ:MLYS) had its price target raised by analysts at Wells Fargo & Company from $26.00 to $50.00. They now have an "overweight" rating on the stock.
9/9
01:53 pm
mlys
Mineralys Therapeutics (NASDAQ:MLYS) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $32.00 to $52.00. They now have a "buy" rating on the stock.
Medium
Report
Mineralys Therapeutics (NASDAQ:MLYS) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $32.00 to $52.00. They now have a "buy" rating on the stock.
9/9
01:24 pm
mlys
What Makes Mineralys Therapeutics, Inc. (MLYS) a Strong Momentum Stock: Buy Now? [Yahoo! Finance]
Medium
Report
What Makes Mineralys Therapeutics, Inc. (MLYS) a Strong Momentum Stock: Buy Now? [Yahoo! Finance]
9/8
08:05 am
mlys
Mineralys Therapeutics (NASDAQ:MLYS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $42.00 price target on the stock.
Low
Report
Mineralys Therapeutics (NASDAQ:MLYS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $42.00 price target on the stock.